Cyclerion Therapeutics (CYCN) Competitors $2.39 -0.50 (-17.30%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$2.31 -0.08 (-3.35%) As of 08/6/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. MRSN, AKTX, MAAQ, ESLA, SNYR, ITRM, DYAI, CLSD, OKUR, and KZRShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Mersana Therapeutics (MRSN), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Estrella Immunopharma (ESLA), Synergy CHC (SNYR), Iterum Therapeutics (ITRM), Dyadic International (DYAI), Clearside Biomedical (CLSD), OnKure Therapeutics (OKUR), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Its Competitors Mersana Therapeutics Akari Therapeutics Mana Capital Acquisition Estrella Immunopharma Synergy CHC Iterum Therapeutics Dyadic International Clearside Biomedical OnKure Therapeutics Kezar Life Sciences Cyclerion Therapeutics (NASDAQ:CYCN) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Do insiders and institutionals believe in CYCN or MRSN? 75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by insiders. Comparatively, 13.0% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor CYCN or MRSN? In the previous week, Mersana Therapeutics had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Mersana Therapeutics and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.38 beat Mersana Therapeutics' score of 0.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cyclerion Therapeutics Positive Mersana Therapeutics Neutral Is CYCN or MRSN more profitable? Cyclerion Therapeutics has a net margin of -89.51% compared to Mersana Therapeutics' net margin of -217.63%. Cyclerion Therapeutics' return on equity of -22.60% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion Therapeutics-89.51% -22.60% -20.61% Mersana Therapeutics -217.63%-990.16%-48.87% Which has stronger valuation and earnings, CYCN or MRSN? Cyclerion Therapeutics has higher earnings, but lower revenue than Mersana Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$2M3.84-$3.06M-$1.16-2.06Mersana Therapeutics$40.50M0.83-$69.19M-$14.75-0.45 Do analysts prefer CYCN or MRSN? Mersana Therapeutics has a consensus price target of $130.00, indicating a potential upside of 1,840.30%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Mersana Therapeutics is more favorable than Cyclerion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mersana Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more volatility & risk, CYCN or MRSN? Cyclerion Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. SummaryCyclerion Therapeutics beats Mersana Therapeutics on 9 of the 16 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.28M$3.01B$5.56B$9.47BDividend YieldN/A2.41%4.31%4.17%P/E Ratio-3.2316.5729.3723.99Price / Sales3.84313.98444.7496.71Price / CashN/A42.1735.8458.51Price / Book0.737.818.085.58Net Income-$3.06M-$54.52M$3.26B$265.35M7 Day Performance-9.81%0.41%0.44%-0.07%1 Month Performance-22.65%9.93%4.82%1.76%1 Year Performance-17.87%15.18%30.27%25.39% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics2.4387 of 5 stars$2.39-17.3%N/A-25.5%$9.28M$2M-3.2330Positive NewsEarnings ReportMRSNMersana Therapeutics3.887 of 5 stars$6.86+3.9%$130.00+1,795.0%-82.3%$32.90M$40.50M-0.47150News CoverageUpcoming EarningsAKTXAkari Therapeutics3.2476 of 5 stars$1.00-0.6%$5.00+398.0%-73.3%$32.50MN/A0.009Gap DownMAAQMana Capital AcquisitionN/A$3.88-6.3%N/A+1,001.6%$31.53MN/A0.001ESLAEstrella Immunopharma2.3617 of 5 stars$0.83-3.1%$16.00+1,831.7%-42.0%$30.92MN/A-3.19N/ASNYRSynergy CHC3.9966 of 5 stars$3.51+4.5%$10.00+184.9%N/A$30.89M$34.83M0.0040ITRMIterum Therapeutics1.5991 of 5 stars$0.71-2.5%$9.00+1,160.9%-39.7%$30.84MN/A-0.7210Earnings ReportShort Interest ↑High Trading VolumeDYAIDyadic International3.2616 of 5 stars$1.01+0.5%$6.00+494.1%-24.2%$30.24M$3.49M-5.057News CoverageUpcoming EarningsGap UpCLSDClearside Biomedical2.4031 of 5 stars$0.42+8.1%$4.20+911.8%-62.2%$29.85M$1.66M-1.0130Upcoming EarningsOKUROnKure Therapeutics2.5724 of 5 stars$2.16-1.8%$32.33+1,396.9%N/A$29.72MN/A-0.41N/AUpcoming EarningsKZRKezar Life Sciences3.6654 of 5 stars$4.10+1.2%$39.50+863.4%-29.3%$29.59M$7M-0.3860Negative NewsUpcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies MRSN Competitors AKTX Competitors MAAQ Competitors ESLA Competitors SNYR Competitors ITRM Competitors DYAI Competitors CLSD Competitors OKUR Competitors KZR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCN Stock Alerts